Keyphrases
Cost-effectiveness
100%
Treatment Strategy
100%
Doxorubicin
100%
Precision Medicine
100%
Prednisone
100%
Cyclophosphamide
100%
Rituximab
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Medicine Treatment
100%
Novel Treatments
60%
Activated B Cells
40%
Germinal Center B Cells
40%
Phase II Trial
20%
Novel Agents
20%
Incremental Cost-effectiveness Ratio
20%
Effective Data
20%
Lenalidomide
20%
Model Discovery
20%
Quality-adjusted Life Years
20%
Microsimulation Model
20%
Chemoimmunotherapy
20%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Doxorubicin
100%
Personalized Medicine
100%
Prednisone
100%
Cyclophosphamide
100%
Rituximab
100%
Diffuse Large B-Cell Lymphoma
100%
Vincristine
100%
B Cell
80%
Health Care Cost
40%
Germinal Center
40%
Lenalidomide
20%
Quality Adjusted Life Year
20%
Chemoimmunotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Prednisone
100%
Cyclophosphamide
100%
Doxorubicin
100%
Vincristine
100%
Rituximab
100%
Diffuse Large B Cell Lymphoma
100%
Lenalidomide
20%
Immunology and Microbiology
B Cell
100%
Prednisone
62%
Cyclophosphamide
62%
Rituximab
62%
Germinal Center
25%
Quality Adjusted Life Year
12%
Lenalidomide
12%